GlaxoSmithKline PLC
featured
Biotech and drug companies say the benefits of genome research are on the way, and just as importantly, advances are pushing the technology toward affordability.
» Read More
More
-
DUBLIN, June 18- U.S.-based Royalty Pharma has dropped a hostile bid worth up to $8 billion for Elan, leaving the Irish drugmaker free to seek other suitors having put itself up for sale last week.
-
SOUTH SAN FRANCISCO, Calif.-- Drug developer Theravance Inc. plans to split into two independent, publicly traded companies after a royalty agreement it had ironed out with Irish drugmaker Elan Corp. PLC fell through. South San Francisco, Calif.- based Theravance said Monday it will split into businesses named Royalty Management Co. and Theravance Biopharma.
-
NEW YORK, June 13- The U.S. Supreme Court decision on Thursday to uphold patent protections for genetic material that has been changed in the laboratory but invalidate patents for purely natural DNA may seem like a partial setback for the biotech industry, but experts said it isn't: the industry has already moved on.
-
*E-cigarettes sold as less harmful alternative to tobacco. LONDON, June 13- Puffing on slim metal tubes loaded with pale yellow liquid, two London businessmen say they have between their lips a cure for what the U.N. calls "one of the biggest public health threats the world has ever faced".
-
LONDON, June 12- Britain is to regulate electronic cigarettes as non-prescription medicines from 2016 in an attempt to improve quality, though the country's drugs watchdog said they would still be sold in convenience stores.
-
LONDON, June 11- British drugmaker GlaxoSmithKline has fired its head of research and development in China after discovering that a study by some of its Chinese scientists contained misrepresentation of data.
-
NEW YORK, June 11- Royalty Pharma, pursuing a hostile $8 billion takeover of Irish drugmaker Elan Corp Plc, moved on Tuesday to make sure it is not blocked by a potential $200 million share buyback and drug spinoff at the target company.
-
June 10- French drugmaker Sanofi SA said the U.S. Food and Drug Administration had approved its four-strain influenza vaccine, which is meant to provide better protection from infection than traditional three-strain flu vaccines.
-
LONDON, June 10- One of the world's longest running drug development sagas may draw to a close this month as French firm Sanofi hopes for a European green light for its new multiple sclerosis medicine Lemtrada.
-
*Purchase takes AstraZeneca into emerging LABA/LAMA market. LONDON, June 10- AstraZeneca is to buy U.S. respiratory drug specialist Pearl Therapeutics for up to $1.15 billion as Britain's second biggest drugmaker steps up a drive to rebuild its product pipeline via deal-making.
-
U.S. health advisers voted on Thursday to recommend modifying market restrictions on GlaxoSmithKline's diabetes drug Avandia, the one-time blockbuster at the center of one of the biggest drug controversies in recent years.
-
WASHINGTON, June 6- U.S. health advisers voted on Thursday to recommend relaxing market restrictions on GlaxoSmithKline's diabetes drug Avandia, the former blockbuster at the center of one of the biggest drug controversies in recent years.
-
DUBLIN/ NEW YORK, June 6- Royalty Pharma received a blow in its battle to take over Irish drug firm Elan on Thursday after a ruling on conditions attached to the U.S. company's hostile bid threatened to scupper the deal.
-
WASHINGTON, June 6- A narrowly divided U.S. Food and Drug Administration panel of outside experts on Thursday voted to modify market restrictions on GlaxoSmithKline's diabetes drug Avandia, the one-time blockbuster at the center of one of the biggest drug controversies in recent years.
-
The two-day FDA advisory committee meeting is not expected to bring about a major boost in sales for the onetime multibillion dollar product. Glaxo has said it has no plans to promote Avandia again, even if the FDA panel recommends lifting restrictions on sales of the drug, whose generic name is rosiglitazone.
-
The two-day FDA advisory committee meeting is not expected to bring about a major boost in sales for the onetime blockbuster product.
-
Avandia's U.S. patent lapsed in 2011, a year after the FDA heavily restricted its use due to ambiguity about possible increased risk of heart attack and stroke seen in a large trial called RECORD, as well as a review of dozens of other studies.
-
"Overall, the readjudication appears to support the previous observation that in this trial, was not associated with an increased incidence of major adverse cardiovascular events," FDA staff members said in documents released by the agency on Monday.
-
CHICAGO, June 1- A cancer drug sold by GlaxoSmithKline was shown in a clinical trial to extend by several months the length of time ovarian cancer patients lived without their disease worsening. Andreas du Bois, professor of gynecologic oncology at Kliniken Essen Mitte in Essen, Germany.
-
*EMC up on dividend, buyback. NEW YORK, May 30- U.S. stock index futures pointed to a modestly higher open on Thursday as the latest economic data indicated that central bank stimulus would remain intact.
Most Popular Video
No reason has been given yet for the departure of founder and executive chairman George Zimmer, reports CNBC's Courtney Reagan. Zimmer has long been the face of the company.
Wednesday, 19 Jun 2013 | 10:52 AM ETCNBC's Rick Santelli, explains why he hears 'crickets" when he asks questions about Fed Chairman Bernanke's policies. "Enough is enough," he rants.
Wednesday, 19 Jun 2013 | 11:36 AM ETAre reporters lobbing "softball" questions at the Fed chairman? CNBC's Rick Santelli and the Wall Street Journal's Jon Hilsenrath, debate whether the economy continues to need quantitative easing. I'm trying to inform the public about what the Fed is up to, says Hilsenrath.